A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Dec 2018 Planned End Date changed from 30 Nov 2018 to 31 Dec 2021.
- 13 Dec 2018 Planned primary completion date changed from 30 Nov 2018 to 31 Dec 2021.
- 31 Aug 2018 Biomarkers information updated